On November 4, 2026, Neurology published a Karolinska Institutet-led study of 352 women from Gothenburg, Sweden. All were aged 70 and had no signs of cognitive impairment, and each had a brain MRI at 70 and again five years later. The researchers compared those scans with each woman's hormonal history: age at first period, age at menopause, past use of the contraceptive pill and use of menopausal hormone therapy (MHT/HRT). They looked at signs of cerebral small vessel disease (damage to the brain's tiniest blood vessels), the microstructure of white matter, and cortical thickness in regions vulnerable to Alzheimer's.

Why It Matters

**It suggests a vascular mechanism for HRT and the brain.** The 2026 case for HRT and brain health has relied on dementia-risk data, such as the 183,000-woman UK Biobank analysis ([our coverage](/stories/hrt-dementia-uk-biobank-183k)) and Stanford's autopsy study of estrogen-only therapy ([our coverage](/stories/estrogen-only-mht-alzheimers-autopsy)). This study points to *how* a benefit might work, through the small blood vessels linked to stroke, cognitive decline and dementia. It is also notable for including oral contraceptive history, which most HRT-and-brain studies leave out. **For menopause telehealth brands, this is a claims-discipline test.** Startups are already selling HRT as "brain protection," and this study will be cited in their marketing. The authors' explicit warning against using it to justify preventive prescribing is the line that regulators and plaintiffs' lawyers will check claims against. It also adds to a busy week for hormone-route evidence: Danish registry data this week tied clot risk to oral rather than transdermal estrogen ([our coverage](/stories/bmj-oral-hrt-clot-risk-transdermal)), while patches, the lower-risk route, remain hard to get ([our coverage](/stories/estradiol-patch-shortage-fda-action)).

The findings. A longer reproductive lifespan, meaning more years between first period and menopause, was linked to less small-vessel disease. The American Academy of Neurology's summary says women with longer reproductive spans had 8% lower odds of showing two or more markers of the disease. MHT use was linked to less small-vessel disease, fewer microbleeds, fewer enlarged spaces around blood vessels and better white-matter microstructure. Women who had used both the pill and later MHT had the healthiest vascular profile. "Our results suggest that hormonal exposure across different periods of a woman's life may have cumulative effects also on the cerebrovascular health in later life," said senior author Anna Marseglia.

The caveats, which the authors state themselves. Hormone use was self-reported, and the study had no detailed data on when treatment started, the dose or the formulation. The study is observational, so it cannot show cause and effect. "The results cannot therefore be used as a basis for recommending hormone therapy for preventive purposes," said first author Giulia Lorenzon (Yale, formerly Karolinska). The work involved Karolinska, Yale, the University of Gothenburg and Harvard Medical School, among others. It was funded by sources including the Swedish Research Council and Sweden's Alzheimer's and Dementia foundations, and the authors report no conflicts of interest.

Sources

Update — 2026-11-06

Initial entry — story first created.